Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer

European Journal of Cancer

Volumn 39, Issue 2, 2003, Pages 196-202

  Smorenburg, C H ^a   Ten Tije, A J ^a   Verweij, J ^a   Bontenbal, M ^a   Mross, K ^b   Van Zomeren, D M ^a   Seynaeve, C ^a   Sparreboom, A ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF FREIBURG   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Elderly patients; Paclitaxel; Pharmacokinetics; Pharmacology

Indexed keywords

CREMOPHOR; PACLITAXEL;

AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG INFUSION; ERYTHRODERMA; FEMALE; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; SKIN TOXICITY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; POLYETHYLENE GLYCOLS;

EID: 0037219633     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00611-1     Document Type: Article

References (35)

1. De Rijke J.M., Schouten L.J., Hillen H.F.P.et al. Cancer in the very elderly dutch population. Cancer. 89:2000;1121-1133.
2. Hutchins L.F., Unger J.M., Crowley J.J.et al. Under-representation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341:1999;2061-2067.
3. Yancik R., Wesley M.N., Ries L.A.G.et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. J. Am. Med. Assoc. 285:2001;885-892.
4. Balducci L., Parker M., Sexton W., Tantranond P. Pharmacology of antineoplastic agents in the elderly patients. Semin. Oncol. 16:1989;76-84.
5. Seidman A., Hudis C.A., Albanel J.et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 16:1998;3353-3361.
6. Zanetta S., Albrand G., Bachelot T.et al. A phase I trial of docetaxel every 21 days in elderly patients with metastatic breast cancer. Ann. Oncol. 11:2000;73. (abstr).
7. D'Hondt R., Paridaens R., Wildiers J.et al. Weekly docetaxel in aged or frail metastatic breast cancer patients. toxicity profile and activity Ann. Oncol. 11:2000;72. (abstr).
8. Hainsworth J.D., Burris H.A., Yardi D.A.et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer. a Minnie Pearl Cancer Research Network phase II trial J. Clin. Oncol. 19:2001;3500-3505.
9. Repetto L., Pietropaolo M., Granata R., Ventura R., Gianni W. Weekly paclitaxel infusion in elderly patients with solid tumors. Tumori. 88:2002;S39-S40.
10. Perez E.A., Vogel C.L., Irwin D.H., Kirshner J.J., Patel R. Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res. Treat. 73:2002;85-88.
11. Kearns C.M., Gianni L., Egorin M.J. Paclitaxel pharmacokinetics and pharmacodynamics. Semin. Oncol. 22:1995;16-23.
12. Brouwer E., Verweij J., De Bruijn P.et al. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab. Dispos. 28:2000;1141-1145.
13. Henningsson A., Karlsson M.O., Vigano L.et al. Mechanism-based pharmacokinetic model for paclitaxel. J. Clin. Oncol. 19:2001;4065-4073.
14. Sparreboom A., De Bruijn P., Nooter K.et al. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B. 705:1998;159-164.
15. Sparreboom A., Loos W.J., Verweij J.et al. Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal. Biochem. 255:1998;171-175.
16. Kouroussis C., Kakolyris S., Mavroudis D.et al. A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors. Am. J. Clin. Oncol. 24:2002;404-407.
17. Egorin M.J., Zuhowski E.G., Thompson B.et al. Age-related alterations in daunorubicin pharmacokinetics. Proc. Am. Soc. Clin. Oncol. 6:1987;38. (abstr).
18. Robert J., Hoerni J. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res. 43:1983;4467-4469.
19. Gauvin A., Pinguet F., Culine S.et al. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin. Cancer Res. 6:2000;2690-2695.
20. Gelman R., Taylor S.G. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer. the elimination of age trends in toxicity by using doses based on creatinine clearance J. Clin. Oncol. 2:1984;1404-1413.
21. Nakamura Y., Sekine I., Furuse K., Saijo N. Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age. Cancer Chemother. Pharmacol. 46:2000;114-118.
22. Fidias P., Supko J.G., Martins R.et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin. Cancer Res. 7:2001;3942-3949.
23. Lichtman S.M., Egorin M., Rosner G.L.et al. Clinical pharmacology of paclitaxel in relation to patient age. CALGB 9762 Proc. Am. Soc. Clin. Oncol. 20:2001;67a. (abstr).
24. Gelderblom H., Mross K., Ten Tije A.J.et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J. Clin. Oncol. 20:2001;574-581.
25. Sparreboom A., Van Zuylen L., Brouwer E. Cremophor EL-mediated alteration of paclitaxel distribution in human blood. clinical pharmacokinetic implications Cancer Res. 59:1999;1454-1457.
26. Van Zuylen L., Verweij J., Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest. N. Drugs. 19:2001;125-141.
27. Van Zuylen L., Karlsson M.O., Verweij J.et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother. Pharmacol. 47:2001;309-318.
28. Van Zuylen L., Gianni L., Verweij J.et al. Interrelationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients. Anticancer Drugs. 11:2000;331-337.
29. Kinirons M.T., Crome P. Clinical pharmacokinetic considerations in the elderly. An update. Clin. Pharmacokin. 33:1997;302-312.
30. Nannan Panday VR, Huizing MT, Van Tellingen O, et al. Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving Taxol. In Nannan Panday V, ed. Clinical Pharmacology of Paclitaxel and Platinum Compounds, Thesis, Utrecht University, Utrecht, The Netherlands, 1998, 109-120.
31. Schmucker D.L. Liver function and phase I drug metabolism in the elderly. a paradox Drugs Aging. 18:2001;837-851.
32. Rahman A., Korzekwa K.R., Grohan J.et al. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54:1994;5543-5546.
33. Stewart C.F., Schuetz E.G. Need and potential for predictive tests of hepatic metabolism of anticancer drugs. Clin. Cancer Res. 6:2000;3391-3392.
34. Sotaniemi E.A., Arranto A.J., Pelkonen O., Pasanen M. Age and cytochrome P450-linked drug metabolism in humans. an analysis of 226 subjects with equal histopathologic conditions Clin. Pharmacol. Ther. 61:1997;331-339.
35. Rivory L.P., Slaviero K.A., Hoskins J.M., Clarke S.J. The erythromycin breath test for the prediction of drug clearance. Clin. Pharmacokin. 40:2001;151-158.